Calcium channel blockers (CCBs), introduced between the 1960s and the 1970s, are widely used for a variety of cardiovascular conditions and have received approval from the U.S. Food and Drug Administration (FDA). The primary FDA-approved indications for CCBs include hypertension, coronary artery disease, and chronic stable angina. Individual agents carry further approvals: verapamil and diltiazem for supraventricular arrhythmias; intravenous nicardipine and clevidipine for short-term treatment of hypertension when oral therapy is not feasible or desirable; and nimodipine for improving neurologic outcome after aneurysmal subarachnoid hemorrhage, given as 60 mg by mouth or enteral tube every 4 hours for 21 days and never intravenously (parenteral administration has caused cardiac arrest and profound hypotension, and the capsules carry a boxed warning against it). These medications have proven highly effective in controlling blood pressure, managing coronary spasm, and relieving chest pain associated with stable angina.
The two major subtypes of CCBs—dihydropyridines and non-dihydropyridines—have distinct uses based on their effects on the heart and vascular system. Dihydropyridines (e.g., amlodipine, nifedipine, felodipine, nicardipine, clevidipine) are potent vasodilators, primarily affecting peripheral vascular resistance. These agents are predominantly used to manage hypertension, coronary artery disease, and chronic stable angina due to their ability to lower blood pressure through vascular smooth muscle relaxation. They are particularly effective in patients who may have isolated systolic hypertension, a condition commonly seen in older adults.
On the other hand, non-dihydropyridines (e.g., verapamil, diltiazem) have more pronounced effects on the heart itself. They are commonly used for conditions such as paroxysmal supraventricular tachycardia (PSVT), both for conversion and prophylaxis, as well as for atrial fibrillation/flutter. In these cases, non-dihydropyridines slow conduction through the sinoatrial (SA) and atrioventricular (AV) nodes, reducing heart rate and myocardial oxygen demand. Additionally, non-dihydropyridines are used to manage chronic stable angina and vasospastic (Prinzmetal) angina, making them versatile agents for a range of cardiovascular disorders.
In addition to FDA-approved uses, CCBs have several off-label applications, including migraine prophylaxis, Raynaud’s phenomenon, hypertrophic cardiomyopathy, vasoreactive pulmonary arterial hypertension, anal fissures, tocolysis in preterm labor, and prevention of high-altitude pulmonary edema. These off-label uses stem from the vasodilatory properties of CCBs, as well as their ability to affect smooth muscle relaxation in various organ systems. However, the use of CCBs in off-label conditions requires careful selection of the specific agent, as not all CCBs are equally effective or safe for every off-label indication.
